A systematic approach to the formulation of anti-onychomycotic nail patches by Kinloch, AJ et al.
Contents lists available at ScienceDirect
European Journal of Pharmaceutics and Biopharmaceutics
journal homepage: www.elsevier.com/locate/ejpb
Research paper
A systematic approach to the formulation of anti-onychomycotic nail
patches
K. Rizia, I.K. Mohammedb, K. Xua, A.J. Kinlochb, M.N. Charalambidesb, S. Murdana,⁎
a Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK
bDepartment of Mechanical Engineering, Imperial College London, London SW7 2AZ, UK
A R T I C L E I N F O
Keywords:
Nail
Patch
Onychomycosis
Pressure-sensitive adhesive
Peel tests
Work of adhesion
Tack
A B S T R A C T
Nail patches have a potential role as drug carriers for the topical treatment of nail diseases such as onycho-
mycosis, a common condition. Our aim was therefore to develop a systematic and novel approach to the for-
mulation of a simple drug-in-adhesive ungual patch. Twelve pressure-sensitive adhesives (PSAs), four backing
membranes, two release liners and three drugs were screened for pharmaceutical and mechanical properties.
From this initial screening, two PSAs, two drugs, one backing membrane and one release liner were selected for
further investigation. Patches were prepared by solvent-casting and characterised. The patches had good uni-
formity of thickness and of drug content, and showed minimal drug crystallisation during six months of storage.
Meanwhile, the drug stability in the patch upon storage and patch adhesion to the nail was inﬂuenced by the
nature of the drug, the PSA and the backing membrane. The reported methodology paves the way for a sys-
tematic formulation of ungual nail patches to add to the armamentarium of nail medicines. Further, from this
work, the best patch formulation has been identiﬁed.
1. Introduction
Onychomycosis, the fungal infection of the nail unit, aﬀects 14–18%
of the general population worldwide [1], and has been called a ‘stub-
born clinical problem’ [2]. Its increasing incidence, signiﬁcant negative
impact on suﬀerers’ quality of life [3] and current treatment limitations
such as liver toxicity of oral drugs and low cure rates of approved to-
pical medicines [4], demand new therapeutic approaches. Accordingly,
we have studied the development of anti-onychomycotic nail patches.
Topical therapy is highly desirable for its avoidance of systemic adverse
eﬀects and drug interactions. Therefore, a range of formulations such as
lacquers, ﬁlms, solutions, hydrogels and UV-curable gels have been
investigated, as compiled in, for example [5,6]. Nail patches have also
been investigated although the literature is very limited. It includes
investigations into the inﬂuence of patch components on ungual (i.e. of
the nail) drug permeation [7,8], testing of sertaconazole-containing
patches in human volunteers[9], and the use of patches in photo-
dynamic therapy of onychomycosis [10] and in iontophoretic ungual
drug delivery[11].
An ideal nail patch should be easy to apply, remain adhered to the
nail plate for the intended duration, release the loaded drug which can
then permeate into the nail, be easy to remove cleanly when desired
and be aesthetically acceptable. The design of a patch is obviously
critical to its performance. Our aim was, for the ﬁrst time, to develop a
systematic approach to the formulation of anti-onychomycotic nail
patches, using a range of pharmaceutical and engineering tools. We
present, in this paper, how these were used to examine and understand
the related material, mechanical, rheological and pharmaceutical
properties of the components and of the prepared patches, in order to
optimise patch development.
The outline of the study is as follows. Firstly, the patch-type was
selected. While various patch types are possible (as exempliﬁed by
commercially available skin patches [12–15]), we chose the drug-in-
adhesive matrix type, where a drug-in-adhesive layer is sandwiched
between a backing layer and a release liner for its simplicity. Secondly,
the drugs terbinaﬁne HCl, amorolﬁne HCl, and ciclopirox olamine,
were selected as the model drugs, since terbinaﬁne HCl is considered
the oral anti-onychomycotic drug of choice in the UK [16], whilst the
topical nail lacquers of amorolﬁne HCl and ciclopirox olamine have
been the most eﬀective topical preparations for many years, prior to the
FDA-approval of Kerydin® and Jublia® in 2014. Thirdly, the other patch
components, namely the adhesive, backing membrane and release liner
were selected. The release liner and the backing layer must be chemi-
cally inert, while the backing layer must also be aesthetically accep-
table and ﬂexible [15]. In addition, we decided to use a water-im-
permeable backing layer in order to produce occlusive patches.
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Occlusivity is expected to increase nailplate hydration, which is known
to favour ungual drug permeation [17]. Enhanced nailplate hydration is
also expected to convert drug-resistant fungal spores into drug-sus-
ceptible fungal hyphae, and this is expected to further enhance the
success of topical anti-fungal therapy.
The adhesive is usually a pressure-sensitive adhesive (PSA), which is
deﬁned as a material which adheres to a substrate with light pressure
and, ideally, leaves no residual adhesive upon its removal. It is one of
the most critical components of the patch [13,18]. The PSA must adhere
to the substrate, be biocompatible as well as compatible with the drug
and excipients, remain stable and functional once formulated in the
patch, provide adequate diﬀusivity to the drug, and be acceptable to the
regulatory authorities [13]. Commonly used PSAs in skin patches in-
clude polyisobutylenes (PIBs), polysiloxanes (silicones) and poly-
acrylate copolymers (acrylics) [13–15], and within each of these
groups, there are many commercially-available options. In this work,
the Hansen Solubility Parameter (HSP) concept was used in order to
select the optimum PSAs which would enable a high drug loading,
which was desired as it could be expected to lead to a large drug re-
servoir in the patch, reduced frequency of patch application and
thereby enhanced patient adherence.
Following selection of the patch components, drug-loaded patches
were prepared, and the preparation method was optimised. Prepared
patches were characterised to enable the optimisation of the formula-
tion of novel anti-onychomycotic nail patches.
2. Materials and methods
2.1. Materials
Amorolﬁne HCl (Ranbaxy Research Laboratories, India), terbinaﬁne
HCl (AK Scientiﬁc, USA) and ciclopirox olamine (Zhejiang Huadee
Chemicals, China) were used as model antifungal drugs. Pressure
Sensitive Adhesives (PSAs) were supplied as solutions of the polymer in
organic solvents, and the solid content of the solutions was gravime-
trically measured. Duro-Tak™ acrylic adhesives (grades: 87-4098, 87-
9301, 87-2852, 87-504A, 87-202A, 87-4287, 87-502A and 87-2525)
were kindly provided by Henkel Ltd, UK. Silicone adhesives, Bio-PSA
4102, Bio-PSA 4202 and Bio-PSA 4302, were obtained from Dow
Corning, USA. Oppanol B15 polyisobutylene adhesive was not used
experimentally, but its HSP values were obtained from the HSPiP
software. Four diﬀerent backing membranes (Scotchpak 9723,
Scotchpak 9733, Scotchpak 9757 and CoTran 9701 were purchased
from 3M, UK. The 3M Scotchpak 9744 (a polyester ﬁlm with a ﬂuor-
opolymer release-coating applied to one side) was selected as the re-
lease liner following initial experiments with two potential liners (i.e.
Scotchpak 1022 and Scotchpak 9744) and the determination of a lack of
signiﬁcant diﬀerence between the two. For the peel tests, three diﬀerent
materials were used as substrates: high density polyethylene (HDPE,
4mm thick, (RS, Corby, UK), Vitro-Nail® (a commercially-available
polymeric material marketed as a possible model for the human nail
plate, IMS Inc., Portland, USA) and human cadaver nails (Tissue
Solutions, UK).
Triﬂuric acid (TFA), phosphoric acid, triethylamine, acetonitrile,
sodium octane sulfonate and methanol were purchased from Sigma-
Aldrich (UK) and were of HPLC grade. Solvents used to determine the
values of the HSP of the PSAs included 1,3-dioxolane, 1-butanol,
1-methyl-2-pyrrolidone, 1-pentanol, 2-(methylamino)ethanol, 2,2,4-
trimethylpentane, 4-hydroxy-4-methyl-2-pentanone (diacetone al-
cohol), acetic acid, acetic anhydride, acetophenone, benzyl alcohol,
benzyl butyl phthalate, butyl acetate, chlorobenzene, chloroform,
dibutyl phthalate, diethylene glycol, DMSO, dodecanol, ethanol, etha-
nolamine, ethylene glycol monomethyl ether, isopropyl palmitate,
methyl ethyl ketone, dichloromethane, N,N-dimethylformamide,
octanol, phosphoric acid, propane, propylene carbonate, p-xylene, tet-
rahydrofuran, toluene, trimethylamine, vinyl pyrrolidone were
obtained from Sigma Aldrich (UK), acetone, acetonitrile, benzaldehyde,
formaldehyde, methanol (Fisher Scientiﬁc, UK) and heptane (BDH
Chemicals Ltd, UK).
2.2. Selection of appropriate pressure sensitive adhesives for high drug
loading
Hansen Solubility Parameters (HSPs) were used to select the ap-
propriate PSAs. HSPs divide the total solubility parameter, δT, into in-
dividual parts arising from dispersion forces, δD, permanent dipole-
permanent dipole forces, δP, and hydrogen bonding forces, δH, [19] as
follows:
= + +δ δ δ δT D P H2 2 2 2 (1)
To determine the compatibility between a PSA and a drug, the so-
lubility parameter ‘distance’ between them (Ra) was calculated from
their respective HSPs as follows:
= − + − + −R δ δ δ δ δ δ( ) 4( ) ( ) ( )a D D P P H H2 2 1 2 2 1 2 2 1 2 (2)
where the subscripts 1 and 2 refer to PSA and drug, respectively.
A smaller Ra indicates higher PSA-drug compatibility, which is ex-
pected to lead to higher drug loading in the patch. Thus, to identify
appropriate PSAs for each anti-fungal drug, the HSPs of the drug and of
the PSAs were determined, and PSA-drug Ra values were calculated.
2.2.1. Determination of the HSPs of the pressure sensitive adhesives and of
the drugs
HSPs of the Duro-Tak™ acrylic adhesives (grades: 87–4098, 87-
9301, 87-2852, 87-504A, 87-202A, 87-4287, 87-502A and 87-2525)
and of the silicone adhesives (Bio-PSA 4102, Bio-PSA 4202 and Bio-PSA
4302) were experimentally determined while the HSP of the poly-
isobutylene PSA (Oppanol B15) was taken from the Hansen Solubility
Parameters in Practice (HSPiP) software (3rd edition 3.1.12, Steven
Abbott TCNF Ltd, UK). For the experimental determination of the va-
lues of the HSPs, small amounts of a PSA or drug were weighed into
vials and a solvent was added to each vial to give a PSA concentration
of 100mg/ml or a drug concentration of 10mg/ml. The mixtures were
stirred at 25 ± 1 °C for 72 h to allow time for complete dissolution, if
this was achievable. The vials were then visually inspected, and the
solvents were scored as: good (i.e. 1) if the PSA had completely dis-
solved in the solvent and bad (i.e. 0), if not. Experiments were con-
ducted in triplicate. The solvent scores were then inputted into the
HSPiP software. This software plots the δD, δP and δH of each organic
liquid along the axes of a 3-dimensional graph, and locates a sphere in
the HSP space that includes all or most of the ‘good’ solvents and ex-
cludes the ‘bad’ ones, with a minimum of error, as indicated by the ‘ﬁt’.
The central coordinates of the sphere give the values of the HSPs (i.e. δD
,δP, δH) of the PSA. Multiple calculations allowed the calculation of the
mean values and standard deviations. For each PSA, between forty and
ﬁfty liquids were tested, and the number of good solvents ranged from
ﬁfteen to thirty four for the diﬀerent PSAs. For each drug, between
thirty three and thirty nine liquids were tested. The HSPs of the drugs
have been reported previously [20]. For both drugs and PSAs, ﬁts of
greater than 0.9 were obtained.
2.2.2. Theoretical and experimental determination of drug-PSA aﬃnities
Once the HSPs of the drugs and PSAs had been determined (Section
2.2.1, their theoretical compatibility (indicated by Ra) was calculated
using Eq. (2). The experimental drug-PSA aﬃnity was measured by
examining drug-in-PSA ﬁlms by polarised light microscopy. Solutions of
drug in PSA (with drug loadings of 0 to 20% w/w) were prepared, cast
over a deﬁned area onto microscope slides, left to dry for 72 h at room
temperature, and the resulting ﬁlms were examined under a Nikon
Microphot-FXA microscope (Tokyo, Japan) for the presence of drug
crystals. Micrographs where taken with a Lumenera Inﬁnity-2 digital
camera (Ottawa, Canada) and analysed with ImageJ software (Version
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1.45s, from the National Institutes of Health, Bethesda, Maryland, USA)
for the percentage area covered in drug crystals.
2.3. Measurement of the mechanical and rheological properties of the PSAs
2.3.1. Casting of the PSAs
The HSPs-based work described above identiﬁed Duro-Tak 87-2852
and Duro-Tak 87-202A (henceforth referred to as Duro-Tak 2852 and
Duro-Tak 202A, respectively) as the optimal PSAs to give the highest
drug loadings. The mechanical and rheological properties of these two
PSAs were therefore characterised. All experiments were performed at
21 °C and 50% humidity, using a Zwick Roell 1.0 mechanical testing
machine (Zwick Testing Machines Ltd., UK) equipped with a 1 kN load
cell. The PSA ﬁlms were prepared by diluting the PSAs with di-
chloromethane (DCM) at a weight ratio of 2:3, casting the solution onto
a release liner (200mm×150mm) which was placed in a mould, al-
lowing the solvent to evaporate for at least 24 h at room temperature,
followed by the placement of a second sheet of release liner on the PSA
surface, thereby creating a liner-PSA-liner sandwich. To prepare drug-
loaded PSA ﬁlms, the drug was dissolved in the PSA-solvent mixture
and the solution was left to stand for 24 h prior to casting.
2.3.2. Determination of the tensile properties of the PSA ﬁlms
Liner-PSA-liner sandwich ﬁlms, prepared as described above, were
cut into 90mm by 10mm samples. One release liner was removed and
the resulting PSA-liner was stuck to the inner surface of the tensile
grips, set 50mm apart. Thus, the value of the tensile gauge length, L,
was 50mm. The second release liner was removed and the PSA ﬁlm was
clamped between the tensile grips. Tensile tests on drug-free and drug-
loaded PSA ﬁlms were performed at constant speeds of 1, 10 and
100mm/min, giving true strain rates of 0.1, 1 and 10/min respectively.
The true stress, σ, and true strain, ε, were calculated from the load, F,
and displacement, δ, data using Eqs. (3) and (4) respectively:
= ⎛
⎝
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where b is the sample width and t is the sample thickness (which
was in the range of 600–800 μm).
2.3.3. Determination of the tack of the PSAs
PSA samples (approximate thickness 200 μm) were prepared by
diluting the PSAs, as described above, casting the solutions onto a high-
density polyethylene (HDPE) surface, and allowing the solvent to eva-
porate for 24 h. A ﬂat steel probe of diameter 6mm was lowered onto
the PSA sample, allowed to dwell for 60 s at dwell forces of 0.5 N, 4.5 N
or 10 N and then pulled oﬀ at a speed of 10mm/min. The resulting
load-displacement data was converted into stress-displacement curves
to obtain the tack strength, σmax, and the tack work of adhesion, Wa,
which was calculated as the area under the curve.
2.3.4. Measurement of surface energies of PSAs and of model nail plates
The surface energies of the Duro-Tak 2852 and Duro-Tak 202A PSAs
and of the model nail plates were measured: (a) as an indicator of the
patch adhesion to the nail plate, since the adhesion is known to depend
on the surface energies of the surfaces involved [14], and (b) to cor-
relate later with the peel tests results. Due to the cost, scarcity and
natural curvature of human nail plates in both directions [21], which
make peel tests challenging, peel tests were also conducted using two
other model substrates, namely, Vitro-Nail® (claimed to mimic the
wetting properties of human ﬁngernails [22] and HDPE, which has
previously been found to be a suitable model for the nail plate in ad-
hesion experiments [23,24]. Model nail plates should have similar
surface energies to that of the human nail plate, given that adhesion is
related to the surface energies of the surfaces involved.
The surface energies of the PSAs and the model nail plates were
determined via the measurement of contact angles formed by droplets
of four liquids (i.e. water, glycerol, diiodomethane and formamide) on
the sample surface using a goniometer. A droplet of a liquid was placed
onto the sample surface using a syringe, imaged using the goniometer
camera and the contact angle was determined. For each liquid, ten
images were taken at two second intervals and the contact angle on
both sides of the droplet of each image was measured. The average of
twenty measurements was taken, and used to calculate the sample’s
surface energy using the Kinloch, Kodokian Watts (KKW) method [25].
Once the surface energies of the PSAs and model nail plates were de-
termined, the thermodynamic work of adhesion, ψa, between the PSA
and the model nail plate was calculated using:
= +ψ γ γ γ γ2 2a S
d
S
d
S
p
S
p
1 2 1 2 (5)
Where γsd and γsp are, respectively, the dispersion force and the
polar force components to the total surface free energy (γS) of a solid,
where γS= γsd + γsp and the numbers 1 and 2 relate to the two ma-
terials (i.e. the PSA and model nail plate).
2.4. Selection of the optimal backing membranes
2.4.1. Determination of the occlusivity of backing membranes
The occlusivity of the backing membranes Scotchpak 9723, 9733,
9757 and CoTran 9701 were assessed by measuring their moisture
vapour transport, as per ISO 2528 (1995) International Standard.
Beakers containing water and enclosed with a backing membrane were
placed in a water-bath at 32 °C (to mimic the body surface temperature)
and weighed at time intervals to measure the water loss from the
beaker.
2.4.2. Determination of the tensile properties of backing membranes
A backing membrane which was stiﬀ enough, so that it would not
deform considerably, and which was strong enough, to prevent patch
breakage upon the latter’s removal from the nail, was required. The
tensile properties of the four backing membranes were therefore as-
sessed at speeds of 10, 100 and 1000mm/min using a 1 kN load cell and
backing membrane samples of 130mm×10mm. The load-displace-
ment data was converted to a stress-strain plot, using Eqs. (3) and (4),
and the Young’s modulus, E, and yield stress, σy, were obtained.
2.4.3. Determination of backing membrane behaviour in peel tests
Peel tests, using a range of backing-membrane/PSA combinations,
adhered to the HDPE model nail plate, were conducted to identify the
optimal backing-membrane/PSA combination, using the set-up as
shown in Fig. 1. Patches were prepared as described in Section 2.5
below, then cut into strips (20mm×80mm). The release liner was
removed and approximately 40mm of the patch strip was stuck to the
HDPE, by rolling a 1 kg weight roller once over the patch, while the
other end of the patch strip was ﬁxed to a tensile grip on the mechanical
testing machine. The HDPE itself was attached to a 80mm×40mm
precision linear slide with a stroke length of 47mm, which ensured the
maintenance of a constant peel angle during the test. Peel tests were
conducted at peel speeds of 1, 10 and 100mm/min and at a peel angle
of 90°.
2.5. Preparation of drug-loaded nail patches
Nail patches were prepared by diluting the purchased PSA solution
with DCM to obtain a PSA concentration of 15% w/w. Diﬀerent
amounts of drugs were added to the polymer solutions to obtain drug
loadings at the dissolved saturation level in each polymer. The mixtures
were then cast onto the selected backing membrane contained in
moulds (7.5 cm×5 cm) and the solvent was allowed to evaporate for
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24 h. Subsequently, the release liner was placed on the PSA surface to
create a backing membrane-PSA-liner sandwich.
2.6. Characterisation of the drug-loaded nail patches for thickness, residual
solvent, and drug load uniformity, homogeneity and stability
Thickness of the prepared patches was measured at ten diﬀerent
positions using a digital micrometer.
Residual solvent in the patch was measured by thermogravimetric
analysis using a Discovery TGA instrument (TA instruments Ltd, UK).
The patches were heated to 80 °C, due to drug instability above 100 °C,
then maintained at 80 °C for one hour until the weight loss remained
constant.
Uniformity of drug content was measured by cutting patches into
1 cm2 sections, which were then weighed and dissolved in 20ml of
methanol. These samples were stirred overnight, sonicated for 30min,
ﬁltered (with a PTFE syringe ﬁlter with a pore size of 0.45 µm) and the
drug content was determined using HPLC (as described below), fol-
lowing appropriate dilution with a 40:60 acetonitrile: water mixture.
Homogeneity of the drug loading in the patch was analysed by Raman
spectroscopy and X-ray photoelectron spectroscopy (XPS). Raman
spectra of patches, drug-free PSAs and pure drugs were obtained using
the Renishaw inVia micro-Raman system equipped with a 300 mW
near-infrared diode laser at a wavelength of 785 nm for excitation
(Renishaw Inc., UK) using a 20x objective lens. Spectra were recorded
with a resolution of 1 cm−1 in the range of 400–3500 cm−1 and ob-
tained for a 10 s exposure of the CCD detector. To establish the drug
distribution within the PSA, depth proﬁling of the patches was per-
formed by scanning their cross sections at eight diﬀerent points at in-
tervals of 40 µm.
XPS was conducted on both surfaces of a drug-loaded PSA layer, as
well as on a cross-section to determine the drug distribution in the
patch. The nitrogen, oxygen and carbon compositions were measured,
with the nitrogen (which is present in the drug, but not in the PSA)
giving evidence of drug presence. To analyse the interior of a patch, the
patch was etched at nine levels for 10 s each time. The XPS instrument
(Thermo K-alpha spectrometer, UK) utilised a 72W monochromated Al
Kα X-ray source, focused to a spot of 400 µm diameter at the sample
surface. The electron energy analyser operated in a constant analyser
energy (CAE) mode with a 128 channel position sensitive detector. The
pass energy was set to 151.2 eV. Spectra were analysed using the
Thermo Avantage software.
To measure drug stability in the patches, the patches were stored for
six months under accelerated (40 °C/75% RH) test conditions and drug
levels were measured at monthly intervals by HPLC, as described
below. In addition, the ciclopirox olamine-loaded patches were stored
under long-term (25 °C/60% RH) test conditions, and were examined
by microscopy at monthly intervals (as described in Section 2.2.2) to
determine the presence and growth of any drug crystals.
HPLC was conducted using a 1260 Inﬁnity Agilent HPLC system
using a Luna C18 column (150×4.6mm, 5 µm). For amorolﬁne HCl
and terbinaﬁne HCl, a ﬂow rate of 1ml/min and an injection volume of
20 µl were used with UV detection at 220 nm and 224 nm respectively.
The mobile phase for amorolﬁne HCl consisted of 0.1% TFA in water
and acetonitrile at a ratio of 55:45 v/v and resulted in the elution of the
drug after 4.8min. For terbinaﬁne HCl, a mobile phase of 0.012M
trimethylamine and 0.020M phosphoric acid was mixed with acetoni-
trile (65:35 v/v). The retention time for terbinaﬁne was 6.1 min. For the
drug ciclopirox olamine, a mobile phase of 5mM sodium octane sul-
fonate in water and acetonitrile (50:50 v/v) was employed using a ﬂow
rate of 2ml/min, a UV detection of 267 nm and an injection volume of
40 µl. This resulted in the elution of ciclopirox olamine at 3.1 min. The
HPLC methods were validated for linearity, accuracy, precision (intra-
day and inter-day) and limits of detection and quantiﬁcation.
2.7. Peel tests on patches
Peel tests on drug-loaded patches (with PSA thickness of approxi-
mately 200 µm) were conducted using the two nail plate models (i.e.
HDPE and Vitro-Nail) as well as a human cadaver nail plate, as de-
scribed in Section 2.4.3, at constant peel speeds of 100mm/min and a
peel angle of 90°. The human cadaver nail plates were softened by
placing them in a hot water bath for approximately ten minutes, then
ﬂattened (by placing a 5 kg weight on top of the nail plates overnight)
and then bonded to a rigid aluminium plate using an epoxy adhesive,
i.e. Araldite® Rapid, UK.
2.8. Statistical analysis
The IBM Statistical Package for the Social Sciences 22 software was
used. In all cases, p≤ 0.05 was used to assess the degree of statistical
signiﬁcance. Repeated-measures ANOVA tests were conducted to
Fig. 1. A schematic of the experimental peel test at 90°.
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determine whether there was any inﬂuence of drug loading on the
tensile properties of the PSAs. A two-way between-groups ANOVA was
conducted to explore the impact of dwell force and of the nature of the
PSA on the tack strength, and on the tack work of adhesion. A two-way
ANOVA was also conducted to explore the inﬂuence of the nature of the
substrates, and of the drug, on the patch peel force.
3. Results and discussion
3.1. Selection and characterisation of the PSAs
3.1.1. Selection of PSAs for high drug loading
The Hansen Solubility Parameters of the PSAs are shown in Table 1.
It can be seen that the experimentally-determined δD, δP and δH para-
meters reﬂected the chemical structures of the PSAs. Thus, the acrylic
and acrylate-vinylacetate PSAs, with their hydroxyl and carboxyl
groups, showed greater values of δP and δH compared to the acrylic-
rubber hybrids, silicone- and polyisobutylene-based PSAs. The HSPs of
the anti-onychomycotic drugs are shown in Table 2. As expected, these
drug salts showed relatively high δP and δH values.
For each PSA-drug combination, the theoretical and experimental
compatibilities are shown in Table 3, which shows a general trend of
decreasing drug solubility in the PSA with increasing Ra (i.e. the solu-
bility parameter ‘distance’ between drug and PSA). Thus, to some ex-
tent, the theoretical and actual compatibilities agree, although the
trend is far from perfect, which shows that, while HSP values can be
used to predict drug-PSA compatibility, the degree of compatibility
must be experimentally conﬁrmed. Table 3 also shows the presence of a
notable outlier, Duro-Tak 2852 PSA, in which the drugs are far more
soluble than in the other PSAs with similar Ra values. It seems that the
carboxylic groups in this PSA enhance drug solubility, possibly due to
interactions with the amine moieties in the drugs, whose chemical
structures are shown in Supplementary ﬁle, 1. The greater solubility of
the ciclopirox olamine compared to those of amorolﬁne HCl and ter-
binaﬁne HCl, could be due to its smaller molecular size (shown in
Table 2), as well as its more basic primary amine group, which could
interact to a greater extent with the carboxylic groups of the Duro-Tak
2852 PSA. For all three drugs, the most promising PSAs are shown to be
the acrylic adhesives, Duro-Tak 2852 and the Duro-Tak 202A, which
enabled the greatest drug loadings.
The suitability of these two PSAs were therefore further examined.
To investigate the inﬂuence of drug loading, if any, on the mechanical
properties of the PSAs, amorolﬁne HCl and ciclopirox olamine were
used at their saturation solubilities in each PSA, i.e. ciclopirox olamine
at 5% in Duro-Tak 202A and at 16% in Duro-Tak 2852; and amorolﬁne
HCl at 3% in Duro-Tak 202A and at 5% in Duro-Tak 2852. Amorolﬁne
HCl and ciclopirox olamine were both included in order to assess the
eﬀects of the nature and concentration of the drug on the properties of
the PSAs. Meanwhile, terbinaﬁne HCl was excluded from further study,
given the similarities in the solubility proﬁles of amorolﬁne HCl and
terbinaﬁne HCl in the diﬀerent PSAs.
3.1.2. Mechanical properties of PSAs
Typical stress-strain curves of the two selected PSAs are shown in
Fig. 2. A large diﬀerence is seen, with the Duro-Tak 2852 showing a
higher modulus and a higher fracture stress. In addition, Duro-Tak 2852
fails in tension at a strain of approximately 2.1 (equivalent to the PSA
ﬁlm stretching approximately seven times its original length) whereas
the Duro-Tak 202A has not yet failed at the maximum test strain
reached (i.e. of 2.4, equivalent to the ﬁlm stretching to ten times its
original length). Thus, Duro-Tak 202A exhibits a greater strain to
failure. This indicates that in practice, i.e. when a patient is peeling a
patch oﬀ from their nail, the Duro-Tak 202A PSA would be more likely
to stretch, making it more diﬃcult and painful to remove. For both
PSAs, an eﬀect of test rate is shown, with a less stiﬀ response at the
lower rate as the viscoelastic PSA has more time to ﬂow and elongate
and therefore needs a smaller force to achieve a given level of strain.
To investigate the inﬂuence of drug loading, Duro-Tak 2852 PSA
was selected due to its stiﬀer mechanical response (which would allow
any changes to be more obvious), and the inﬂuences of amorolﬁne HCl
and ciclopirox olamine addition are shown in Fig. 3. For both drugs, a
less stiﬀ stress-strain response was seen, compared to the drug-free
control (p < 0.05), that is, the drugs plasticise the PSA. The plasti-
cising eﬀect of amorolﬁne HCl was very similar to that of ciclopirox
olamine (repeated-measures ANOVA p > 0.05), despite its much lower
concentration, i.e. 5% versus 16% (or 0.01mol versus 0.06mol per
100 g). This shows that the plasticisation eﬀect was not due to the
Table 1
Hansen Solubility Parameters of PSAs considered for use in ungual patches. HSPs were experimentally determined except for Oppanol B15*, whose HSP values were taken from the
Hansen Solubility Parameters in Practice (HSPiP) software. Means ± SD are shown.
Hansen Solubility Parameters (MPa½)
PSA name Description Functional groups δD δP δH
Duro-Tak 87-202A Acrylic –OH 17.2 ± 0.3 8.7 ± 0.5 6.5 ± 0.3
Duro-Tak 87-2852 Acrylic –COOH 16.4 ± 0.2 5.6 ± 0.3 6.9 ± 0.2
Duro-Tak 87-9301 Acrylic none 16.4 ± 0.1 5.5 ± 0.3 6.7 ± 0.3
Duro-Tak 87-4287 Acrylate- vinylacetate –OH 16.6 ± 0.1 6.1 ± 0.1 6.1 ± 0.1
Duro-Tak 87-2525 Acrylate-vinylacetate –OH 16.6 ± 0.1 6.3 ± 0.3 6.4 ± 0.1
Duro-Tak 87-4098 Acrylate-vinylacetate none 16.6 ± 0.1 6.4 ± 0.1 6.6 ± 0.1
Duro-Tak 87-504A Acrylic-rubber hybrid –OH 15.8 ± 0.2 1.2 ± 0.4 5.4 ± 0.5
Duro-Tak 87-502A Acrylic-rubber hybrid –OH 15.7 ± 0.3 2.3 ± 0.2 4.8 ± 0.3
Bio-PSA 4102
Bio-PSA 4202
Bio-PSA 4302
Silicone –Si(CH3)3 16.1 ± 0.1 1.9 ± 0.4 5.0 ± 0.2
Oppanol B15 Polyisobutylene None 18.8* 1.5* 1.3*
Table 2
Hansen Solubility Parameters of drugs considered for use in ungual patches, from [20].
The mean and (SD) values are shown. Molar volumes and log P are predicted values from
Chemistry Dashboard https://comptox.epa.gov/dashboard).
Drug Hansen Solubility
Parameters (MPa½)
Other properties
from https://comptox.epa.gov/
dashboard)
δD δP δH MW (Da) Molar
volume
(cm3)
Log Partition
coeﬃcient P
Amorolﬁne HCl 18.1
(0.4)
12.2
(0.5)
16.9
(0.3)
354 343 5.3
Terbinaﬁne HCl 17.1
(0.7)
16.6
(1.1)
13.9
(0.6)
328 289 5.9
Ciclopirox olamine 17.4
(0.6)
13.9
(0.6)
17.2
(0.6)
268 174 2.1
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amount of drug loaded in the PSA, but rather due to the chemical
nature of the drugs which would govern any drug-PSA interactions. In
practice, any reduction in the stiﬀness of the PSA by drug loading could
lead to a greater diﬃculty being encountered during patch removal
from a nail plate, as the PSA would stretch more and tend to ﬁbrillate
rather than peel oﬀ the nail.
3.1.3. Tack of the PSAs
The tack strength, σmax, and the tack work of adhesion, Wa, of the
two PSAs are shown in Fig. 4. As expected, increasing the dwell force
increased the tack strength and the tack work of adhesion for both PSAs
(p < 0.05). Duro-Tak 2852 showed a greater tack strength compared
to the Duro-Tak 202A at all dwell forces (p < 0.05). From this ob-
servation, it was expected that Duro-Tak 2852 PSA would give a higher
tack work of adhesion compared to Duro-Tak 202 PSA. Surprisingly,
this was not so. The opposite was observed, which is related to the way
the tack work of adhesion, Wa, was calculated, i.e. from the area under
the stress-displacement curve. The value ofWa was higher for Duro-Tak
202A as its tensile failure occurred at a much greater displacement than
for Duro-Tak 2852, in agreement with the tensile results shown in
Section 3.1.2. These results indicate that, while a higher stress may be
Table 3
Theoretical and experimental determinations of PSA-drug compatibility. Theoretical determinations are shown by Ra, where the larger the Ra, the lower the compatibility. Experimental
determinations are shown by the drug concentration (%w/w) loaded into a PSA at which drug crystals start to appear.
PSA name Terbinaﬁne HCl Amorolﬁne HCl Ciclopirox olamine
Ra Drug concentration at which crystals start to
appear (%)
Ra Drug concentration at which crystals start to
appear (%)
Ra Drug concentration at which crystals start to
appear (%)
Duro-Tak 202A 11 4 11 4 12 6
Duro-Tak 2852 13 8 12 7 13 17
Duro-Tak 9301 13 1 13 2 14 1
Duro-Tak 4287 13 2 13 1 14 3
Duro-Tak 2525 13 2 12 2 13 1
Duro-Tak 4098 13 1 12 1 13 1
Duro-Tak 504A 18 1 17 1 18 3
Duro-Tak 502A 17 1 16 1 17 3
Bio-PSA 4102
Bio-PSA 4202
Bio-PSA 4302
17 1 16 1 17 1
Oppanol B15 20 ND 19 ND 20 ND
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 0.5 1 1.5 2 2.5
Tr
ue
 S
tr
es
s 
[M
Pa
]
True Strain
Duro-Tak 2852
Duro-Tak 202A
100 mm/min
100 mm/min
10 mm/min
10 mm/min
Fig. 2. Typical tensile stress-strain curves of the drug-free PSAs: Duro-Tak 2852
( ) and Duro-Tak 202A ( ); at test speeds of 10 and 100mm/
min.
0
0.05
0.1
0.15
0.2
0.25
0.3
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Tr
ue
 S
tr
es
s 
[M
Pa
]
True Strain
Drug free
Ciclopirox olamine
Amorolfine HCl
Fig. 3. Typical tensile stress-strain curves at a testing true strain rate of 1 min−1 for drug-
free and drug-loaded Duro-Tak 2852 PSAs. The ciclopirox olamine drug was present at
16% w/w while the amoroﬁne HCl drug was present at 5% w/w.
Fig. 4. Tack strength, σmax, and tack work of adhesion, Wa, for the drug free Duro-Tak
2852 ( ) and Duro-Tak 202A ( ) PSAs adhering to the HDPE substrate. Means and SDs
(error bars) are shown. N=4–5.
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needed to remove a patch based on Duro-Tak 2852 PSA from a nail
plate, more energy will be needed to remove a patch containing Duro-
Tak 202A, as the latter adhesive elongates to a greater extent while it is
being peeled oﬀ from a nail plate. In practice, the higher Wa for Duro-
Tak 202A might lead to more ﬁbrillation (due to its ability to deform
more easily) and potentially lead to undesired PSA residue remaining
on the nail plate upon patch removal from a nail. Meanwhile, the higher
tack strength of Duro-Tak 2852 would mean that it is less likely to fall
oﬀ during normal wear, although the higher force needed to remove the
patch when desired may mean a more painful patch removal.
3.1.4. Surface energies of the PSAs and of model nail plates and PSA-nail
thermodynamic work of adhesion
The surface energies of the model nail plates and of the PSAs are
shown in Table 4. It can be seen that the surface energies of the various
PSAs are fairly similar in value, with the dispersion component making,
by far, the greater contribution. The surface energies of the PSAs being
approximately 30mJ/m2 is promising for their application in ungual
patches, given that for good intrinsic adhesion, the surface energy of the
adhesive must be equal to, or less than, that of the substrate[14], and
that the surface energy of the human nailplate in vivo has been found to
be 34.1 ± 5.5mJ/m2 [26]. The surface energy of 38mJ/m2 for HDPE
is in good agreement with previously reported values of 35mJ/m2 [27]
and 40mJ/m2 [23], and is close to the surface energy of a human nail
plate [26]. Thus, HDPE appears to be a better model for the human nail
plate than Vitro-Nail and is therefore used in the peel experiments re-
ported below. The values of the thermodynamic work of adhesion, ψa,
between the model nail plates and the PSAs are also shown in Table 4. It
can be seen that ψa is somewhat higher for the PSAs adhering to the
Vitro-Nail, which is due, of course, to its higher surface energy com-
pared to HDPE. Otherwise, there is little diﬀerence in the values of ψa
amongst the various PSAs.
Drug inclusion in the PSA has a minimal inﬂuence on the surface
energy of the PSAs and consequently on the thermodynamic work of
adhesion, which is possibly due to (a) the relatively small amounts of
drug in the PSAs, and (b) the fact that the drug was in a molecularly
dispersed form, rather than a particulate form whose relatively large
size could have changed the surface and interface properties.
It is worth commenting here that the thermodynamic work of ad-
hesion, ψa, is orders of magnitude smaller that the tack work of adhe-
sion, Wa, shown in Fig. 4. This was expected due to the highly viscous
dissipative deformation of the PSA, which accompanies the interface
rupturing, and so leads to Wa > > ψa.
3.2. Selection of the backing membrane
3.2.1. Colour, thickness and moisture vapour transmission rates
The polymeric nature, colour, thickness and moisture vapour
transmission rates of the four backing membranes are shown in Table 5.
All the backing membranes are relatively thin (≤ 50 µm). The tan
colour of Scotchpak 9723 is presumably due to the fact that it is sup-
plied for the fabrication of skin patches [28] and the tan colour would
provide a degree of camouﬂage when a patch is worn on the skin. For
application to a nail patch, however, a translucent backing membrane
would be more appropriate and provide a greater camouﬂage and pa-
tient acceptability. CoTran 9701 is much more permeable to water
vapour than the other backing membranes and is therefore less suitable,
given that an occlusive patch was desired as explained earlier.
3.2.2. Tensile properties of backing membranes
Considerable diﬀerences were found in the stress-strain proﬁles,
Young’s modulus and yield stress of the backing membranes (Fig. 5,
Table 5). CoTran 9701, had the lowest yield stress of 5MPa, with the
stress levelling oﬀ beyond this point and thus was the easiest membrane
to deform, in contrast to Scotchpak 9723, 9733 and 9757, which
showed plastic-strain hardening, i.e. an increase in the stress with in-
creasing strain beyond the initial yield stress.
3.2.3. Behaviour of the backing membranes in peel tests
Peel tests were performed on backing membrane-PSA combinations
adhered to the model HDPE nail substrate. During removal of a patch
from a nail plate, a clean interfacial failure at the patch-substrate in-
terface is desired as shown in Fig. 6a and c. However, a clean interfacial
failure was not always achieved. As may be seen from Fig. 6, in some
instances, (a) the PSA ﬁbrillated (Fig. 6b) sometimes leaving PSA re-
sidue on the backing and HDPE surfaces (Fig. 6d), (b) delamination
occurred at both the backing membrane/PSA and the PSA/HDPE in-
terfaces (Fig. 6e) or (c) full debonding did not occur due to the patch
stretching during peeling (Fig. 6f).
The visual observations in Fig. 6 were reﬂected in the load-dis-
placement curves obtained during the peel tests (Fig. 7a and b) and can
be explained by the nature and tensile properties of the backing
membranes. Patches containing the Scotchpak 9723 backing membrane
showed a non-steady state peeling force proﬁle, as they failed at both
the backing-membrane/PSA and the PSA/substrate interfaces (see
Fig. 6e). This is likely to be due to the fact that the Scotchpak 9723
backing membrane is composed of a polyethylene/polyester bilayer.
Table 4
The surface energies of the HDPE and Vitro-Nail model nail plates and of the selected
PSAs. NA: not applicable. NT: not tested; amorolﬁne HCl-loaded Duro-Tak 2852 was not
tested.
Surface energies [mJ/m2] Work of adhesion, ψa
[mJ/m2]
γsd γsp γs HDPE Vitro-Nail
HDPE 37 1 38 NA NA
Vitro-Nail 44 6 50 NA NA
Human nail* *34.1 ± 5.5
Duro-Tak 2852 29 0.8 29.8 68 76
2852+ ciclopirox
olamine
28 1.1 29.1 67 76
2852+ amorolﬁne HCl NT NT NT NT NT
Duro-Tak 202A 34 0.1 34.1 72 79
202A+ ciclopirox
olamine
31 0.0 31.0 69 75
202A+ amorolﬁne HCl 30 0.2 30.2 68 75
* Value of surface energy of human nail measured in vivo from [26].
Table 5
Properties of backing membranes tested. Means and SDs are shown.
Backing membrane Material (colour) from Technical Data Sheets Thickness (µm)
N=4–5
Vapour transport (mg/cm2/
day) N=4–5
Young’s Modulus (GPa)
N=7–9
Yield Stress (MPa)
N=7–9
Scotchpak 9757 Polyester ﬁlm (transparent) 14.0 ± 1.6 2.9 ± 0.06 4.31 ± 0.16 70 ± 4.3
Scotchpak 9733 Laminate of polyester and an ethylene vinyl
acetate copolymer layer (translucent)
48.5 ± 1.9 2.3 ± 0.55 1.38 ± 0.08 24 ± 1.4
Scotchpak 9723 Laminate of pigmented polyethylene and
polyester (tan)
38.8 ± 1.0 2.2 ± 0.46 1.95 ± 0.05 37 ± 3.1
CoTran 9701 Polyurethane ﬁlm (translucent) 50.3 ± 0.5 19.4 ± 0.29 0.054 ± 0.005 5 ± 0.4
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During the peel test, the PSA was sandwiched between two materials
(i.e. the polyethylene surface of the backing membrane and the HDPE
substrate) which possessed relatively similar surface energies. Thus,
similar intrinsic adhesion existed at both the backing-membrane/PSA
and at the PSA/HDPE interfaces which had led to the patch debonding
at both interfaces during peeling. Meanwhile, patches containing Co-
Tran 9701 backing membrane showed very low peeling forces due to its
relatively low modulus and yield stress (as shown in Table 5, which
resulted in incomplete patch-substrate debonding and patch stretching
(see Fig. 6f). Considerably high peak peel forces with a stick-slip action
due to the formation of ﬁbrils at the peel front were obtained with the
Scotchpak 9757/Duro-Tak 202A combination (Fig. 7b). In contrast the
Scotchpak 9733/Duro-Tak 202A patch showed a relatively smooth
continuous, force proﬁle with less pronounced peaks and troughs due to
the relatively large ﬁbrils which were observed (see Fig. 6d). Patches
containing the backing membranes Scotchpak 9757 or Scotchpak 9733
together with the Duro-Tak 2852 PSA showed relatively uniform
steady-state peeling force proﬁles, reﬂecting the desirable clean inter-
facial failures seen in Fig. 6a and c.
3.2.4. Final selection of backing membranes from appearance, tensile and
peel tests
From Sections 3.2.1– .2.3, CoTran 9701 and Scotchpak 9723
backing membranes were eliminated. CoTran 9701 backing membrane
was eliminated due to its high moisture permeability and low modulus,
which would result in non-occlusive patches that stretch and fail to
debond fully during patch removal from a nail. Scotchpak 9723 backing
membrane was eliminated due to patch debonding at both the backing-
membrane/PSA and PSA/nail interfaces during patch peeling. These
eliminations left Scotchpak 9733 and Scotchpak 9757 as potential
backing membranes. As can be seen from Fig. 6a and c, the use of either
backing membranes resulted in optimal patch peeling, when combined
with Duro-Tak 2852 PSA, resulting in clean interfacial failure at the
PSA/model nail interface. From these two choices, Scotchpak 9757 was
favoured over Scotchpak 9733 due to a much lower peel force required
for patch removal from a model nail plate and its higher Young’s
modulus and yield stress. These aspects mean that the Scotchpak 9757
backing membrane was (a) less likely to considerably deform, elasti-
cally or plastically, and hence the force required to remove the patch
would not greatly increase during patch peeling oﬀ a nail in practice
and (b) not likely to break during patch removal from a nail. Thus,
Scotchpak 9757 was selected as the backing membrane for subsequent
patch development.
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3.3. Patch preparation and characterisation
Following the above selection of (a) the two PSAs (i.e. Duro-Tak
202A and Duro-Tak 2852), (b) the two drugs (i.e. ciclopirox olamine
and amorolﬁne HCl), (c) the backing membrane (i.e. Scotchpak 9757)
and (iv) the release liner (i.e. Scotchpak 9744), nail patches were pre-
pared. Firstly, the PSAs (purchased as liquids where the PSA was dis-
solved in organic solvents with solid contents of 42.4 ± 0.4% w/w for
Duro-Tak 202A PSA and 36.5 ± 0.3% w/w for Duro-Tak 2852 PSA)
were diluted with DCM (i.e. a good solvent for both the drugs and the
PSAs). Dilution was needed to reduce the viscosity, enable good
spreading upon casting and the formation of uniform adhesive layers.
Following PSA dilution, the drug was dissolved at the appropriate
concentrations to reach saturation solubility in the PSA, the solution
was cast onto the backing membrane, the organic solvent was evapo-
rated oﬀ and the release liner was then applied to the PSA layer, to
prepare nail patches. These nail patches, which were based upon our
proposed systematic approach to the formulation of a simple drug-in-
adhesive ungual patch, were characterised as described below.
3.3.1. Patch thickness, residual solvent, drug content and distribution
The patches were between 380 and 480 μm thick, with relatively
good uniformity of thickness (Supplementary ﬁle, S2). Drug content
was 3% w/w amorolﬁne HCl in Duro-Tak 202A, 5% w/w amorolﬁne
HCl in Duro-Tak 2852, 5% w/w ciclopirox olamine in Duro-Tak 202A
and 16% w/w ciclopirox olamine in Duro-Tak 2852. The drug con-
centration in the patch was selected to be slightly less than the drug
levels at which drug crystals would start to appear (shown in Table 3),
to ensure that all the loaded drug was fully dissolved in the PSA. The
absence of drug crystals was conﬁrmed using polarised light micro-
scopy.
Except for the ciclopirox olamine in Duro-Tak 2852, only relatively
low amounts of drug could generally be loaded in the PSA in the pat-
ches in the dissolved form due to the fairly low solvency of the PSAs for
the drugs and the evaporation of most of the solvent during patch
preparation, which resulted in low residual solvent levels of below 2%
w/w in the patches (Supplementary ﬁle, S3). The drug was dispersed
uniformly within the full thickness of the patches for 5% w/w amor-
olﬁne HCl in Duro-Tak 2852 patches, as shown by Raman spectra taken
at eight depths (Supplementary ﬁle, S4). However, Raman depth pro-
ﬁling of the other three patches showed higher levels of the drugs in the
top layer of the patches (Supplementary ﬁle, S4). This is probably due
to some degree of drug movement during solvent evaporation, as the
drugs travel to the top with the solvent and accumulate at the patch
surface. Similarly, and for the same reason, XPS analysis of the patch
surface and interior showed drug presence throughout the patch
thickness, although drug levels in the patch was not totally uniform
(Supplementary ﬁle, S5).
3.3.2. Drug stability in patches
Polarised light micrographs of patches stored under accelerated and
long-term test conditions showed negligible crystallisation of ciclopirox
olamine over the six months storage. Indeed, image analysis of the
micrographs showed that drug crystals occupied areas of less than 1%
(Supplementary ﬁle, S6). The limited drug recrystallization in the pat-
ches is in agreement with reports of a similar lack of crystallisation of
ethinyl estradiol and levonorgestrel in Duro-Tak 2074 and Duro-Tak
202A acrylic PSAs [29] where the authors suggested that polymeric
acrylic adhesives could have inhibitory eﬀects on drug crystallisation
due to their carboxyl/hydroxyl functional groups, which might act as
hydrogen acceptors and donors, and thereby immobilise drug molecules
and prevent crystallisation.
Periodic analysis of the drug content of the patches stored at 40 °C/
75% RH showed a greater chemical stability of the amorolﬁne HCl
compared to the ciclopirox olamine (Fig. 8). In both patches, amor-
olﬁne HCl levels remained at 100% of the initial concentration over
6months. In contrast, while the ciclopirox olamine level remained the
same in the Duro-Tak 202A based patch, its level in the Duro-Tak 2852
based patch decreased to about 50% of the initial drug load after six
months. That is, in the latter case, the ciclopirox olamine was degrading
with time. Furthermore, visual observations of the patches showed that
the ciclopirox olamine loaded Duro-Tak 2852 based patches gradually
became more yellow in colour with time (Supplementary ﬁle, S7).
Greater degradation of ciclopirox olamine in Duro-Tak 2852 could be
due to an inherent instability of the drug and/or be related to the nature
of the adhesive. Duro-Tak 202A and Duro-Tak 2852 are both acrylic
polymers, with diﬀerences in their functional groups (Table 1, and
viscosity, Tg and Young’s modulus (which are all higher for Duro-Tak
2852 as shown in Supplementary ﬁle, S8). It is possible that interaction
between ciclopirox olamine and the carboxyl groups in the Duro-Tak
2852 PSA enhances drug degradation, which would be reﬂected in the
greater ciclopirox olamine degradation reported in acidic media [30].
Ciclopirox olamine degradation in other formulations (based on Po-
loxamer 407) and the generation of a yellowish discolouration has also
been reported [31], as has its degradation by sunlight and UV light
[32]. It seems that ciclopirox olamine possesses an inherent instability,
and the present results, and those from the literature, indicate that
formulations using this drug would need to be formulated at higher pH
and should be protected from light. Thus, for ciclopirox-olamine con-
taining nail patches, light-excluding opaque backing membranes might
be more appropriate than transparent ones.
3.3.3. Peel properties of patches
Patches containing Duro-Tak 2852 PSA and Scotchpak 9757
backing membrane, which demonstrated an acceptable peeling beha-
viour from the model HDPE nail plate (Figs. 6 and 7a) were selected to
measure the peel force, which give an indication of how easy it would
be for a patient to remove an ungual patch from their nail. Upon peeling
from human cadaver nail or model nail (i.e. HPDE or Vitro-Nail) sub-
strates, debonding occurred cleanly at the desired PSA/substrate
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interface for all three substrates, and the steady-state maximum peel
forces are shown in Fig. 9. In general, the peel forces were lowest for the
HDPE substrate, and highest for the Vitro-Nail substrate (two-way
ANOVA, p < 0.05), reﬂecting the diﬀerences in their surface energies
and the PSA-model nail thermodynamic works of adhesion (Table 4).
However, the correlation is not perfect, with the peel forces for the
HDPE substrate being lower than those for the human nail plate sub-
strate (p < 0.05), despite their similar surface energies. It is possible
that the higher peel forces obtained for the human nail were due to the
higher surface roughness of the human nail, which would increase the
surface area for adhesion and thereby increase the peel force. Drug
loading in the patch increased the peel force (p < 0.05), with the two
drugs having similar eﬀects (p > 0.05). The lower peel force for the
drug-free formulation can be correlated with the stiﬀer stress-strain
response shown in Fig. 4, as stiﬀer adhesives often lead to lower peel
forces [33]. Fig. 9 also shows that the patch/human nail peel forces are
typically in between those for the patch/HDPE and patch/Vitro-Nail
interfaces. Consequently, the HDPE and Vitro-Nail model substrates
may be used as model nails for in vitro peel tests to give an indication of
the forces required to remove ungual patches from human nails.
4. Conclusions
Our aim was to develop a new systematic approach to the for-
mulation of drug-in-adhesive anti-onychomycotic nail patches, and in
this paper, we demonstrate a possible pathway for such patch devel-
opment. We started the proposed patch development methodology with
the testing of each patch component individually, for example, testing
the tensile properties of the possible PSAs. However, we have found
that there are signiﬁcant interactions between the patch components,
for example PSA plasticisation by the drug and patch peeling behaviour
dictated by PSA-backing membrane interactions. Thus, as we have de-
monstrated, it may be more appropriate to start the development
methodology using combinations of patch components, and subse-
quently to assess the individual components of the most promising
combinations, and then to select patch components and combinations
for optimal formulation. The signiﬁcant interactions among the patch
components also mean that knowledge about the individual patch
components may not always be transferable when a diﬀerent drug is
formulated.
From the work described in the present paper, the best patch for-
mulation (one that is occlusive, can be peeled oﬀ the nail plate cleanly
and where the drug remains stable upon patch storage) has been
identiﬁed as one containing Scotchpak 9757 backing membrane, Duro-
Tak 2852 PSA, the drug amorolﬁne HCl and Scotchpak 9744 release
liner. The reported methodology paves the way for a systematic and
novel approach to the formulation of simple drug-in-adhesive ungual
patches for the topical treatment of nail diseases.
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